GGrantIndex
← Leaderboards

Mary Eapen

Medical College Of Wisconsin

$20,614,610
Attributed
$41,229,220
Total exposure
5
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $21.4M · FY201525
$25M$18.8M$12.5M$6.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$41,229,220 · 5

By mechanism

OT3$32,852,194 · 1
R01$4,780,411 · 1
R38$1,852,150 · 2
U01$1,744,465 · 1

Top collaborators

Most similar at Medical College Of Wisconsin

Same institution · by research overlap

Others in their field

Top investigators on “National Heart, Lung, And Blood Institute

Research focus

National Heart, Lung, And Blood InstituteInnovationResearch PersonnelDesignWisconsinLearningHematologyFundingMedical SchoolsSickle Cell AnemiaSuccessCollaborationsBloodSickle CellResourcesEnsureGene TherapyLeadTransplantationRecruitMeetingsInternational CenterMaintenanceFaculty

Grant awards (21)

Medical College of Wisconsin Physician Scientist Immersion Program$192,924
R38 · FY2025 · HL
Medical College of Wisconsin Physician Scientist Immersion Program$368,035
R38 · FY2024 · HL
Cure Sickle Cell$352,315
OT3 · FY2024 · HL · contact PI
Cure Sickle Cell$13,557,758
OT3 · FY2023 · HL · contact PI
Cure Sickle Cell$3,729,772
OT3 · FY2023 · HL · contact PI
Cure Sickle Cell$2,340,191
OT3 · FY2023 · HL · contact PI
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies$1,577,015
R01 · FY2023 · HL
Medical College of Wisconsin Physician Scientist Immersion Program$195,119
R38 · FY2023 · HL
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies$1,589,707
R01 · FY2022 · HL
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies$1,613,689
R01 · FY2021 · HL
Stimulating Access to Research in Residency (StARR)$274,018
R38 · FY2021 · HL
Cure Sickle Cell$9,872,158
OT3 · FY2020 · HL
Stimulating Access to Research in Residency (StARR)$274,018
R38 · FY2020 · HL
Hematopoietic Stem Cell Transplantation for Young Adults with SCD - DCC$370,715
U01 · FY2019 · HL · contact PI
Stimulating Access to Research in Residency (StARR)$274,018
R38 · FY2019 · HL
Cure Sickle Cell$3,000,000
OT3 · FY2018 · HL · contact PI
Hematopoietic Stem Cell Transplantation for Young Adults with SCD - DCC$360,752
U01 · FY2018 · HL · contact PI
Stimulating Access to Research in Residency (StARR)$274,018
R38 · FY2018 · HL
Hematopoietic Stem Cell Transplantation for Young Adults with SCD - DCC$361,056
U01 · FY2017 · HL · contact PI
Hematopoietic Stem Cell Transplantation for Young Adults with SCD - DCC$294,286
U01 · FY2016 · HL · contact PI
Hematopoietic Stem Cell Transplantation for Young Adults with SCD - DCC$357,656
U01 · FY2015 · HL · contact PI